BioCentury

8:00 AM GMT, Jan 26, 2009
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Targets lead Novartis to MDx

The new molecular diagnostics business unit at Novartis AG is the next logical step in a drug discovery strategy focused on pathways and targets that was initiated with the hiring of Mark Fishman to head the Novartis Institutes for BioMedical Research in 2002. By developing companion diagnostics for targeted therapies, the pharma expects to be better able to navigate a world in which payers will be looking to limit the use of high-priced drugs to those patients most likely to benefit

Read the full 819 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.